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Abstract 
Introduction. Malignancy is a major complication in the management of solid organ transplant patients. Skin cancers 
show a better prognosis than other neoplasms, but not all others are equal: Ideally, patient management must take into 
account the natural history of each type of cancer in relation to the transplanted organs. We sought to determine the 
prognosis of various groups of noncutaneous nonlymphomatous (NCNL) cancers after heart transplantation (HT). 
Methods. We retrospectively analyzed the records of the Spanish Post-Heart-Transplant Tumour Registry, which 
collects data on posttransplant tumors in all patients who have undergone HT in Spain since 1984. Data were 
included in the study up to December 2008. We considered only the first NCNL post-HT tumors. 
Results. Of 4359 patients, 375 developed an NCNL cancer. The most frequent were cancers of the lung (n = 97; 
25.9%); gastrointestinal tract (n = 52; 13.9%); prostate gland (n = 47; 12.5%; 14.0% of men), bladder (n = 32; 8.5%), 
liver (n = 14; 3.7%), and pharynx (n = 14; 3.7%), as well as Kaposi's sarcoma (n = 11; 2.9%). The corresponding 
Kaplan-Meier survival curves differed significantly (P < .0001; log-rank test), with respective survival rates of 47%, 
72%, 91%, 73%, 36%, 64%, and 73% at 1 year versus 26%, 62%, 89%, 56%, 21%, 64%, and 73% at 2 years; and 
15%, 51%, 77%, 42%, 21%, 64%, and 52% at 5 years post-diagnosis, respectively. 
Conclusion. Mortality among HT patients with post-HT NCNL solid organ cancers was highest for cancers of the 
liver or lung (79%–85% at 5 years), and lowest for prostate cancer (23%). 
Malignancy is one of the main causes of death after heart transplantation (HT).1 The prognosis is better 
for skin cancer than for lymphomas or noncutaneous solid tumors,2 but little is known of differences in 
life expectancy among patients with noncutaneous nonlymphomatous (NCNL) tumors. Ideally, patient 
management should take into account the natural history of each type of cancer, which may differ from its 
natural history among nontransplant patients. Most studies of post-HT malignancy have concerned single 
centers and/or short follow-up periods.3 and 4 In this study, we have determined survival rates among 
patients with various types of NCNL cancer using the records of the Spanish Post-Heart-Transplant 
Tumour Registry (SPHTTR), which collects data on posttransplant tumors in all patients who have 
undergone HT in Spain since 1984.2 
Methods 
Patients 
Candidates for inclusion in the study were the 5301 patients who, according to the SPHTTR, underwent 
HT between 1984 and December 2008 when aged ≥15 years. Of these 5301, we excluded 942 who died 
within 3 months of HT. Of the remaining 4359, 729 (16.7%) developed 997 tumors before January 2009: 
517 skin cancers (51.8%), 81 lymphomas (8.1%), and 399 NCNL tumors (40.1%). This study concerned 
the 375 first post-HT tumors that were NCNL. The study protocol was approved by the clinical research 
ethics committee of each collaborating center. 
  
Statistical Analysis 
The variables were the location and histopathologic type of tumor, the date of diagnosis, the date of death, 
and the survival status at the end of the study period (December 31, 2008). Kaplan-Meier curves for 
survival after diagnosis were constructed using data for 368/375 patients with first NCNL post-HT 
tumors, 7 of which were discovered post mortem. The significance of differences among the Kaplan-
Meier curves of the various types of NCNL tumors was estimated using a log-rank test. The criterion for 
statistical significance was P < .05. 
Results 
The 375 patients with first post-HT tumors that were NCNL constituted 51.4% of the 729 patients 
developing tumors; 8.6% of the 4359 patients at risk. Some 90.1% of the 375 were men. The mean value 
± standard deviation (SD) of age at HT was 54.6 ± 9.3 years, with 54 (14.4%) subjects <45 years; 110 
(29.3%), aged 45–54 years; 166 (44.3%), aged 55–64 years; and 45 (12.0%), aged ≥65 years. The mean ± 
SD follow-up time after tumor diagnosis was 2.6 ± 3.1 years. 
The 7 most common types of first NCNL tumors were, in descending order, cancers of the lung (n = 
97; 25.9%), gastrointestinal tract (n = 52; 13.9%), prostate gland (n = 47; 12.5%; with 14.0% of men), 
bladder (n = 32; 8.5%), liver (n = 14; 3.7%), and pharynx (n = 14; 3.7%), as well as Kaposi's sarcoma (n 
= 11; 2.9%). Figure 1 shows the corresponding Kaplan-Meier postdiagnosis survival curves, which 
differed significantly (P < .0001). The actuarial 1-year survival rates were 47% for lung cancer, 72% for 
gastrointestinal cancer, 91% for prostate cancer, 73% for bladder cancer, 36% for liver cancer, 64% for 
pharynx cancer, and 73% for Kaposi's sarcoma. The corresponding 2-year rates were 26%, 62%, 89%, 
56%, 21%, 64%, and 73%; and the 5-year rates were 15%, 51%, 77%, 42%, 21%, 64%, and 52%, 
respectively. 
 
 
 
Fig 1. Kaplan-Meier survival curves for the 7 most common types of noncutaneous nonlymphomatous tumor among Spanish heart 
transplant patients. 
  
Among the 37 women with first tumors of a NCNL type, there were 7 cervical cancers (19%), 5 breast 
cancers (14%), 2 endometrial cancers (5%), 2 ovarian cancers (5%), and 1 cancer of the vulva (3%), but 
survival statistics for these types were not calculated because of the small numbers of cases. 
Discussion 
Overall, the 5-year survival rate among Spanish HT patients developing NCNL tumors was about 32%,2 
confirming differences among neoplasms, as are known among the general population. Five-year survival 
rates, for example, in decreasing order were prostate (77%) > pharyngeal (64%) > Kaposi's (52%) ≈ 
gastrointestinal (51%) > bladder (42%) > liver (21%) > lung (15%) cancer. As far as we know, evidence 
for differences of this kind have only previously come from small, single-center studies, such as that of 
El-Hamamsy et al.4 These differences are important, because they may influence the therapeutic approach 
to various types of cancer. For a condition with a relatively optimistic prognosis such as prostate gland 
cancer, it may be hypothesized that the oncological benefits of a severe reduction in immunosuppression 
might be outweighed by the accompanying increase in the risk of rejection. It remains to be seen whether 
such dilemmas will be irrelevant by the advent of mammalian target of rapamycin inhibitors, the use of 
which, together with partial or total withdrawal of calcineurin inhibitors, has been reported to slow the 
progression of cancer in patients with kidney grafts.5, 6 and 7 
Although classification differences and other issues prevent direct comparisons of percentages, the 
survival rates (prostate > pharyngeal > Kaposi's ≈ gastrointestinal > bladder > liver > lung cancer) may be 
compared, for example, with those observed 5-year rates for 55–64 and 65–74 year-olds in the 
EUROCARE-4 study of cancer in the European population in general (7): prostate > bladder > 
gastrointestinal tract ≈ pharyngeal > lung > liver cancer. The worse relative prognoses of lung cancer and 
cancer of the bladder invite further research. 
The main weakness of this study was that, because of the limitations of the SPHTTR, it failed to 
distinguish between deaths from cancer and those from other causes. It also naturally shares the 
drawbacks common to all registry-based studies, which derive from the heterogeneity of the treatments, 
which were decided by each patient's medical team at their own discretion. Its strength is its size: 4359 
patients at risk including, 375 who developed NCNL cancers. 
In conclusion, the mortality among HT patients with post-HT NCNL solid organ cancers varied 
widely among types of cancer. It was greatest for cancers of the liver or lung (79%–85% at 5 years), and 
lowest for prostate cancer (23%). 
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Appendix 
The following investigators also contribute to the Spanish Post-Heart Transplant Tumor Registry: Maria J 
Paniagua, Raquel Marzoa, Eduardo Barge (Hospital Universitario A Coruña, La Coruña); Javier Segovia 
and Manuel Gomez-Bueno (Clinica Puerta de Hierro, Madrid); Jesús Palomo y Fernández-Yáñez 
(Hospital General Universitario Gregorio Marañón, Madrid); Sonia Mirabet, Marta Camprecios and 
Eulalia Roig (Hospital de la Santa Creu i San Pau, Barcelona); Luis Martinez-Dolz (Hospital 
Universitario La Fe, Valencia); Monica Fernandez-Valls (Hospital Universitario Marqués de Valdecilla, 
Santander); Miguel Angel Gómez-Sanchez and Pilar Escribano (Hospital Universitario 12 de Octubre, 
Madrid); Josep Roca (Hospital Universitario de Bellvitche, Barcelona); Maria Martin-Fernández and Jose 
L. Rodriguez-Lambert (Hospital Universitario Central de Asturias, Oviedo); Matias Ubilla (Clínica 
Universitaria de Navarra, Pamplona); Carmen Segura Saint-Gerons (Hospital Universitario Reina Sofia, 
Córdoba); Ernesto Lage Gallé (Hospital Universitario Virgen del Rocío, Sevilla), Félix Perez-Villa 
(Hospital Clinic i Provincial, Barcelona); Maria Luisa Sanz-Julve (Hospital Universitario Miguel Servet, 
Zaragoza); and Iris P. Garrido (Hospital Universitario Virgen de la Arrixaca, Murcia); Javier López-Diaz 
(Hospital Clinico Universitario, Valladolid). 
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